4.4 Article

Interaction Kinetic and Structural Dynamic Analysis of Ligand Binding to Acetylcholine-Binding Protein

Journal

BIOCHEMISTRY
Volume 49, Issue 37, Pages 8143-8154

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/bi1006354

Keywords

-

Funding

  1. Commission of the European Communities [HEALTH-F4-2008-202088]
  2. Dutch Top Institute Pharma [D2.103]

Ask authors/readers for more resources

The mechanism of agonist interactions with Cys-loop ligand-gated ion channels has been studied using the acetylcholine-binding protein (AChBP) from Lymnaea stagnalis as a model protein and acetylcholine, nicotine, epibatidine, and a series of substituted quinuclidines as ligands. A biosensor-based assay for direct interaction studies of immobilized AChBP and small molecule ligands was developed. It allowed the characterization of the interaction kinetics of the ligands and the structural dynamics of the protein. The interactions with AChBP were very sensitive to variations in the experimental conditions and showed several types of complexities. These could be resolved into two types of ligand-induced secondary effects with different kinetics, representing fast and slow conformational changes. The data could be rationalized in a mechanistic model, and a structural interpretation of the interaction was obtained by molecular modeling involving induced fit and loop flexibility simulations. The data suggest that AChBP exhibits ligand-induced structural dynamics, as expected for the ligand gating mechanism of Cys-loop receptors. It shows that, the formation of the initial encounter complex between AChBP and ligands is very rapid, in accordance with the functional characteristics required of neurotransmission. These developed procedures will enable further exploration of the mechanism of Cys-loop receptor function and the identification of specific ligands suitable for pharmacological use.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Engineering, Industrial

Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma

Angelo K. S. Romasanta, Peter van der Sijde, Iwan J. P. de Esch

Summary: This study explores how researchers in big pharma firms engage with knowledge from an emerging field, and how they adapt their activities to overcome uncertainties. By focusing on internal and external activities, proponents of novel technologies bridge the developments in the field with the rest of the firm, leading to the adoption and development of the technology.

TECHNOVATION (2022)

Article Chemistry, Medicinal

Fragment-to-Lead Medicinal Chemistry Publications in 2020

Iwan J. P. de Esch, Daniel A. Erlanson, Wolfgang Jahnke, Christopher N. Johnson, Louise Walsh

Summary: The review summarizes successful fragment-to-lead studies published in 2020 and discusses trends and best practices in fragment libraries, target proteins, screening technologies, hit-optimization strategies, and properties of hit fragments and leads. Trends and innovations identified in the review promise to further increase the success of FBDD by developing novel screening fragments, improving screening technologies, using computer-aided design and virtual screening, and combining FBDD with other drug-discovery technologies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Puckering the Planar Landscape of Fragments: Design and Synthesis of a 3D Cyclobutane Fragment Library

David J. Hamilton, Marieke Beemsterboer, Caroline M. Carter, Jasmina Elsayed, Rilana E. M. Huiberts, Hanna F. Klein, Peter O'Brien, Iwan J. P. de Esch, Maikel Wijtmans

Summary: Fragment-based drug discovery has a growing need for unique screening libraries. Cyclobutane moiety, identified as an attractive three-dimensional scaffold, was used to synthesize a library of novel 3D cyclobutane fragments. The library exhibited favorable shape and physicochemical properties compared to existing synthetic 3D fragment libraries.

CHEMMEDCHEM (2022)

Article Chemistry, Medicinal

Exploring the Activity Profile of TbrPDEB1 and hPDE4 Inhibitors Using Free Energy Perturbation

Lorena Zara, Francesca Moraca, Jacqueline E. Van Muijlwijk-Koezen, Barbara Zarzycka, Robert Abel, Iwan J. P. de Esch

Summary: This study evaluated a method for predicting drug affinity in the treatment of African trypanosomiasis. The researchers found that this method accurately predicted the activity of different proteins and overcame challenges such as protein flexibility and sequence conservation. Therefore, this method holds promise for designing more selective inhibitors for African trypanosomes.

ACS MEDICINAL CHEMISTRY LETTERS (2022)

Article Biochemistry & Molecular Biology

Fragment Screening Yields a Small-Molecule Stabilizer of 14-3-3 Dimers That Modulates Client Protein Interactions

Hendrik J. Brink, Rick Riemens, Stephanie Thee, Berend Beishuizen, Daniel da Costa Pereira, Maikel Wijtmans, Iwan de Esch, Martine J. Smit, Albertus H. de Boer

Summary: In this study, a fragment-based drug screening approach was used to identify a PPI stabilizer targeting 14-3-3. The stabilizer was found to cooperatively stabilize 14-3-3 and enhance its binding to client proteins. This finding provides a tool compound for investigating the interactions between 14-3-3 and client proteins.

CHEMBIOCHEM (2022)

Article Chemistry, Medicinal

SAR exploration of the non-imidazole histamine H3 receptor ligand ZEL-H16 reveals potent inverse agonism

Gabor Wagner, Tamara A. M. Mocking, Xiaoyuan Ma, Inna Slynko, Daniel Da Costa Pereira, Robin Breeuwer, Niek J. N. Rood, Cas van der Horst, Henry F. Vischer, Chris de Graaf, Iwan J. P. de Esch, Maikel Wijtmans, Rob Leurs

Summary: In this study, the structure-activity relationship analysis of derivatives of ZEL-H16 revealed that both basic moieties and their distance from the central core are essential for H3R affinity. However, contrary to previous reports, ZEL-H16 and its derivatives were found to act as inverse agonists for G alpha(i) signaling in this study. Docking studies and molecular dynamics simulations identified ionic interactions/hydrogen bonds as crucial interaction points with H3R residues D114 and E206.

ARCHIV DER PHARMAZIE (2023)

Article Biochemistry & Molecular Biology

To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?

Yang Zheng, Susanne Schroeder, Georgi K. Kanev, Sanaa S. Botros, Samia William, Abdel-Nasser A. Sabra, Louis Maes, Guy Caljon, Carmen Gil, Ana Martinez, Irene G. Salado, Koen Augustyns, Ewald Edink, Maarten Sijm, Erik de Heuvel, Iwan J. P. de Esch, Tiffany van der Meer, Marco Siderius, Geert Jan Sterk, David Brown, Rob Leurs

Summary: This study investigated the potential of Schistosoma mansoni phosphodiesterase SmPDE4A as a new drug target for schistosomiasis. The researchers cloned, isolated, and characterized the full-length and catalytic domains of SmPDE4A. They found that SmPDE4A resembles human PDE4 more than parasite PDEs. Screening of PDE inhibitors identified tetrahydrophthalazinones and benzamides as potential hits, but further evaluation showed that the inhibitors were not effective against S. mansoni, suggesting that SmPDE4A is not a suitable target for anti-schistosomiasis therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Green Drug Discovery: Novel Fragment Space from the Biomass-Derived Molecule Dihydrolevoglucosenone (Cyrene™)

Tom Dekker, Jaap W. W. Harteveld, Gabor Wagner, Max C. M. de Vries, Hans Custers, Andrea C. van de Stolpe, Iwan J. P. de Esch, Maikel Wijtmans

Summary: Biomass-derived molecules have the potential for sustainable drug discovery, but their exploration is hindered by the dominance of old-fashioned screening compounds in classical high-throughput screening libraries. We propose a fragment-based drug discovery approach as an efficient method to navigate biomass-derived drug space. In a proof-of-concept study using dihydrolevoglucosenone (Cyrene TM), we generated a diverse fragment library with good physicochemical properties and potential for novel drug candidates based on renewable resources.

MOLECULES (2023)

Article Multidisciplinary Sciences

Amino acid substitutions in human growth hormone affect secondary structure and receptor binding

Andrei Rajkovic, Sandesh Kanchugal, Eldar A. Abdurakhmanov, Rebecca Howard, Sebastian Warmlander, Joseph Erwin, Hugo A. Barrera Saldana, Astrid Graslund, Helena Danielson, Samuel Coulbourn Flores

Summary: The interaction between human Growth Hormone (hGH) and hGH Receptor (hGHR) has important implications in cancer and growth disorders, and hGH has been engineered to improve its binding properties. This study focuses on the E174 substitution in hGH, which has been shown to increase binding but lacks an explanation. The results suggest that the E174A substitution increases affinity of hGH against hGHR by slowing down the off-rate more than the on-rate, highlighting the link between structure, zinc binding, and hGHR-binding affinity in hGH.

PLOS ONE (2023)

Article Multidisciplinary Sciences

Micro-foundations of dynamic capabilities to facilitate university technology transfer

Zhongxuan Ma, K. D. Augustijn, I. J. P. De Esch, B. A. G. Bossink

Summary: This study investigates the micro-foundations of dynamic capabilities in university technology transfer through qualitative case studies at two organizations. The micro-foundations of sensing include selecting internal competency and sensing external partners, while seizing involves resource co-allocation and collaborative business model. The micro-foundations of reconfiguring include strategic renewal, establishing a university technology transfer-friendly environment, and asset orchestration. This study provides better understanding of how dynamic capabilities facilitate university technology transfer, and offers suggestions for industrial practitioners and policymakers.

PLOS ONE (2023)

Article Chemistry, Medicinal

An Automated, Open-Source Workflow for the Generation of (3D) Fragment Libraries

Tom Dekker, Mathilde A. C. H. Janssen, Christina Sutherland, Rene W. M. Aben, Hans W. Scheeren, Daniel Blanco-Ania, Floris P. J. T. Rutjes, Maikel Wijtmans, Iwan J. P. de Esch

Summary: The success of fragment-based drug discovery (FBDD) is closely related to library design. A workflow in KNIME software has been created to guide the design of fragment libraries, considering chemical diversity and novelty of the fragments, as well as their three-dimensional (3D) character. This design tool can create large and diverse libraries or select representative compounds to enrich existing libraries.

ACS MEDICINAL CHEMISTRY LETTERS (2023)

Article Chemistry, Medicinal

PSW-Designer: An Open-Source Computational Platform for the Design and Virtual Screening of Photopharmacological Ligands

Icaro A. Simon, Evert J. Homan, Maikel Wijtmans, Michael Sundstrom, Rob Leurs, Iwan J. P. De Esch, Barbara A. Zarzycka

Summary: The researchers have developed an open-source computational platform, called PSW-Designer, for the design and screening of new photoswitchable ligands, especially for GPCRs. Through two case studies, they validate the predictive capabilities of the platform and anticipate that it will facilitate the design of improved photoswitchable molecules.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2023)

Article Biochemistry & Molecular Biology

The Crystal Structure of Tyrosinase from Verrucomicrobium spinosum Reveals It to Be an Atypical Bacterial Tyrosinase

Mostafa Fekry, Khyati K. Dave, Dilip Badgujar, Emil Hamnevik, Oskar Aurelius, Doreen Dobritzsch, U. Helena Danielson

Summary: Tyrosinases are enzymes involved in melanin production, and the vsTyr is a unique bacterial tyrosinase that does not require a caddie protein and shares similarity with plant-derived members of the enzyme family.

BIOMOLECULES (2023)

Article Oncology

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress

Nadilly Bonagas, Nina M. S. Gustafsson, Martin Henriksson, Petra Marttila, Robert Gustafsson, Elisee Wiita, Sanjay Borhade, Alanna C. Green, Karl S. A. Vallin, Antonio Sarno, Richard Svensson, Camilla Gokturk, Therese Pham, Ann-Sofie Jemth, Olga Loseva, Victoria Cookson, Nicole Kiweler, Lars Sandberg, Azita Rasti, Judith E. Unterlass, Martin Haraldsson, Yasmin Andersson, Emma R. Scaletti, Christoffer Bengtsson, Cynthia B. J. Paulin, Kumar Sanjiv, Eldar Abdurakhmanov, Linda Pudelko, Ben Kunz, Matthieu Desroses, Petar Iliev, Katarina Farnegardh, Andreas Kramer, Neeraj Garg, Maurice Michel, Sara Haggblad, Malin Jarvius, Christina Kalderen, Amanda Bogedahl Jensen, Ingrid Almlof, Stella Karsten, Si Min Zhang, Maria Haggblad, Anders Eriksson, Jianping Liu, Bjorn Glinghammar, Natalia Nekhotiaeva, Fredrik Klingegard, Tobias Koolmeister, Ulf Martens, Sabin Llona-Minguez, Ruth Moulson, Helena Nordstrom, Vendela Parrow, Leif Dahllund, Birger Sjoberg, Irene L. Vargas, Duy Duc Vo, Johan Wannberg, Stefan Knapp, Hans E. Krokan, Per Arvidsson, Martin Scobie, Johannes Meiser, Pal Stenmark, Ulrika Warpman Berglund, Evert J. Homan, Thomas Helleday

Summary: This study investigates the role of MTHFD2 in cancer cells and the effects of its inhibitors. The results demonstrate that MTHFD2 inhibitors can decrease DNA replication speed, induce replication stress, and ultimately lead to apoptosis in cancer cells. These findings reveal the functional link between MTHFD2-dependent cancer metabolism and replication stress, providing a potential therapeutic strategy.

NATURE CANCER (2022)

Article Biochemistry & Molecular Biology

Target 2035-update on the quest for a probe for every protein

Susanne Mueller, Suzanne Ackloo, Arij Al Chawaf, Bissan Al-Lazikani, Albert Antolin, Jonathan B. Baell, Hartmut Beck, Shaunna Beedie, Ulrich A. K. Betz, Gustavo Arruda Bezerra, Paul E. Brennan, David Brown, Peter J. Brown, Alex N. Bullock, Adrian J. Carter, Apirat Chaikuad, Mathilde Chaineau, Alessio Ciulli, Ian Collins, Jan Dreher, David Drewry, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Stephen Frye, Stephen M. Fuchs, Matthew D. Hall, Ingo Hartung, Alexander Hillisch, Stephen H. Hitchcock, Evert Homan, Natarajan Kannan, James R. Kiefer, Stefan Knapp, Milka Kostic, Stefan Kubicek, Andrew R. Leach, Sven Lindemann, Brian D. Marsden, Hisanori Matsui, Jordan L. Meier, Daniel Merk, Maurice Michel, Maxwell R. Morgan, Anke Mueller-Fahrnow, Dafydd R. Owen, Benjamin G. Perry, Saul H. Rosenberg, Kumar Singh Saikatendu, Matthieu Schapira, Cora Scholten, Sujata Sharma, Anton Simeonov, Michael Sundstrom, Giulio Superti-Furga, Matthew H. Todd, Claudia Tredup, Masoud Vedadi, Frank von Delft, Timothy M. Willson, Georg E. Winter, Paul Workman, Cheryl H. Arrowsmith

Summary: Twenty years after the first draft of the human genome was published, our understanding of the human proteome is still incomplete. The majority of proteins in the human proteome remain uncharacterized, with only a small percentage successfully targeted for drug discovery. Target 2035 aims to bridge this gap by developing new technologies for the entire human proteome by 2035.

RSC MEDICINAL CHEMISTRY (2022)

No Data Available